Swarada Suresh Joshi

Dr. Swarada Suresh Joshi


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2026 in Cancers
Verified
Journal Article
Open access
PDF file
MPManas Pustake
Manas Pustake
ARAtharva Railkar
Atharva Railkar
SOStevenson Ongsyping
Stevenson Ongsyping
SJSwarada Suresh Joshi
Swarada Suresh Joshi
OOOboseh Ogedegbe
Oboseh Ogedegbe
RGRohan Garje
Rohan Garje
Background: Prostate cancer remains one of the most prevalent malignancies and a leading cause of cancer-related mortality among men in the United States, with more than 300,000 new cases diagnosed annually. As the burden of disease continues to rise, ensuring equitable access to effective treatment remains a critical public health priority. Unequal access to definitive surgical management among disadvantaged populations may contribute to preventable morbidity and mortality. Radical prostatectomy is a cornerstone treatment for localized disease; however, its utilization has evolved over time in response to changing screening guidelines, technological advancements, and shifting treatment paradigms. Despite these developments, disparities in access to surgical management persist. Methods: Using the Surveillance, Epidemiology, and End Results database, we conducted a retrospective cohort study evaluating factors associated with radical prostatectomy utilization among 917,194 men with localized or regional prostate cancer diagnosed between 2004 and 2022. Multivariable logistic regression assessed demographic, socioeconomic, and clinical predictors of surgical treatment. Results: Overall, 33.5% of patients underwent radical prostatectomy. Increasing age was strongly associated with lower odds of surgery (OR 0.904 per year, 95% CI 0.903–0.904, p < 0.001), while married patients were significantly more likely to undergo prostatectomy (OR 1.601, 95% CI 1.554–1.649, p < 0.001). Black patients had markedly lower odds of surgery compared with White patients (OR 0.547, 95% CI 0.539–0.555, p < 0.001), whereas Asian/Pacific Islander patients had slightly higher odds (OR 1.082, p < 0.001). More recent year of diagnosis and increasing income were associated with modest reductions in prostatectomy utilization. Conclusions: These findings demonstrate that treatment selection in prostate cancer is influenced not only by disease characteristics but also by sociodemographic factors, highlighting persistent disparities in access to definitive surgical care and the need for targeted interventions to improve equity in treatment delivery.

1 April 2026 in Journal of Family Medicine and Primary Care
Verified
Journal Article
Open access
MPManas Pustake
Manas Pustake
VGVeeravenkata Garikiparthy
Veeravenkata Garikiparthy
MGMohammed Arfat Ganiyani
Mohammed Arfat Ganiyani
OOOboseh John Ogedegbe
Oboseh John Ogedegbe
SJSwarada Suresh Joshi
Swarada Suresh Joshi
RGRohan Garje
Rohan Garje
A BSTRACT: Background: Cancer screening is vital for early detection and improved survival, yet disparities persist among marginalized groups. Sexual and gender minority (LGBTQ+) populations face barriers to preventive care, including discrimination, limited access to affirming providers, and socioeconomic inequities. This study evaluates differences in mammogram, cervical, and colorectal cancer screening between LGBTQ+ and non-LGBTQ+ adults using nationally representative data. Materials and Methods: We conducted a cross-sectional analysis using the latest Behavioral Risk Factor Surveillance System. Of 278,519 respondents, participants were categorized as LGBTQ+ ( n = 14,603) or non-LGBTQ+ ( n = 258,942) after excluding missing data. Descriptive statistics and Chi-square tests assessed demographic and screening differences. Logistic regression models estimated associations between sexual orientation and screening uptake, adjusting for age, race/ethnicity, education, and income. Statistical significance was set at α =0.05. Results: LGBTQ+ respondents were younger and reported lower education and income compared to non-LGBTQ+ adults. Significant disparities were found in mammogram screening (χ 2 = 21.85, P < 0.001). Bisexual individuals (odds ratio [OR] =5.37, 95% confidence interval [CI]: 2.24–12.88, P < 0.001) and those identifying with “other” sexual orientations (OR = 2.96, 95% CI: 1.09–8.00, P = 0.033) were less likely to receive mammograms compared to heterosexual individuals. After adjustment, no significant differences were observed for cervical ( P = 0.462) or colorectal screening ( P = 0.709). Sexual orientation predicted only mammogram utilization. Conclusions: Disparities in cancer screening persist, particularly in mammogram use among bisexual and other LGBTQ+ individuals. These findings highlight the need for targeted public health interventions, culturally competent care, and inclusive data collection to reduce structural barriers and improve screening equity for LGBTQ+ populations.